# A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors

> **NCT07537881** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 326 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RC288 For Injection
- **DRUG:** RC288 For Injection

## Key facts

- **NCT ID:** NCT07537881
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2029-12-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 326 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07537881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07537881, "A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07537881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*